Gene Therapy Vectors Articles & Analysis
21 news found
Caroline Man Xu, Co-founder and CEO of ViGeneron said:” Recombinant AAV vectors are an established platform for effective gene therapies today. ...
The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. ...
This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. ...
The calf was administered the AAV9 gene therapy vector at 40 hours of life. Following AAV therapy, biomarker measurements indicated a significant restoration of the missing enzymatic activity. ...
(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene ...
NRC researchers are re-engineering AAV-LPL using new adeno-associated viral (AAV) derived vectors to advance the LPLD gene therapy originally developed at the University of British Columbia. ...
The product manager of the company is excited to launch the Gene Therapy Products Characterization service to help clients overcome the challenges of gene therapy analytical development, which include characterization, quality control, and the need to meet increasingly demanding regulatory expectations. Gene ...
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene ...
These expansions in Greenville, NC; Monza and Ferentino, IT; and Swindon, UK increase manufacturing capacity for sterile liquid and lyophilized filling, and pre-filled syringes. Demand for Cell & Gene Therapy Thermo Fisher's continued investment in cell and gene therapy services is focused on delivering manufacturing ...
Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. ...
Accelerating Demand for Cell & Gene Therapy Thermo Fisher's continued investment in cell and gene therapy services is focused on delivering manufacturing expertise and capacity to support customers at key points along the pathway to commercialization. Thermo Fisher will open its new cGMP plasmid DNA manufacturing facility ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. ...
The capsid of Adeno-associated Virus (AAV) is a naturally occurring, replication-deficient, virus that is widely considered the frontrunner for solving the delivery problem in gene therapy. These viruses are known to be harmless to humans, and are relatively simple to manipulate. One well-known drawback of natural capsids however, which are currently used for delivery, is that many patients with ...
The efficiency of our AI platform only grows as we engage with more partners to produce delivery vectors for different tissues and indications. This is why Dyno’s approach has generated interest from companies that are industry leaders in gene therapy. Better delivery vectors are impactful and easy to adopt for current ...
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ...
(Nasdaq: BIIB, Cambridge, Mass., USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft2 facility will commence in Q4 2020 and will be dedicated to the ...
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy ...
March 05, 2020 – OXFORD, UK – PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. ...